Hengrui’s HER2-Targeted ADC and Antibody Drug Combo Approved for Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical trial approval from...
Daiichi Sankyo
Daiichi Sankyo’s Datroway Approved in Japan for HR+, HER2- Breast Cancer
Japan-based pharmaceutical company Daiichi Sankyo (TYO: 4568) has announced that it has received marketing approval...
Daiichi Sankyo and AstraZeneca Withdraw EU Application for Datopotamab Deruxtecan in Lung Cancer
Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced the voluntary...
Jiangsu Hengrui’s Trastuzumab Rezetecan on Track for NMPA’s Breakthrough Therapy Designation
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading pharmaceutical company based in China, has...
Daiichi Sankyo and AstraZeneca’s Datopotamab Deruxtecan Earns FDA Breakthrough Therapy Designation
Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced that their...
Daiichi Sankyo Invests RMB 1.1 Billion in New ADC Manufacturing Plant in Shanghai
Japanese pharmaceutical company Daiichi Sankyo (TYO: 4568) is significantly increasing its investment in China with...
Daiichi Sankyo and AstraZeneca File BLA for Datopotamab Deruxtecan in NSCLC
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN), partners in the development of innovative...
Alteogen Secures Exclusive Licensing Deal with Daiichi Sankyo for Subcutaneous Enhertu
Alteogen Inc. (KOSDAQ: 196170), a South Korea-based biotechnology company, has announced an exclusive licensing agreement...
Daiichi Sankyo and Alteogen Sign $300 Million Deal to Develop Subcutaneous Enhertu
Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has entered into a potentially $300...
Daiichi Sankyo’s Pexidartinib Poised for Priority Review in China for TGCT Treatment
The official website of the Center for Drug Evaluation (CDE) under China’s National Medical Products...
MSD and Daiichi Sankyo’s Patritumab Deruxtecan Achieves Milestone in Phase III Lung Cancer Trial
Global healthcare leaders Merck, Sharp & Dohme Inc.(MSD; NYSE: MRK), known as MSD outside the...
Merck and Daiichi Sankyo’s HER3-DXd ADC Patritumab Deruxtecan Passes Phase 3 Trial After FDA Rejection
Merck (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) announced that their antibody-drug conjugate (ADC) patritumab...
Merck and Daiichi Sankyo’s Ifinatamab Deruxtecan Shows Promising Results in Phase II ES-SCLC Trial
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK), a leading U.S. pharmaceutical company, and its...
Daiichi Sankyo Launches Tarlige for Diabetes Peripheral Neuropathic Pain in China
Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has announced the official market launch...
Enhertu Gains Conditional Approval in China for Advanced HER2-Positive Gastric Cancer
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate co-developed by AstraZeneca (NASDAQ: AZN, LON: AZN) and...
Daiichi Sankyo and MSD Broaden Partnership to Co-Develop T-Cell Engager MK-6079
Daiichi Sankyo (TYO: 4568), a Japanese pharmaceutical company, has announced an expansion of its strategic...
Daiichi Sankyo Reports 24.3% YOY Revenue Growth, Driven by Enhertu and Lixiana
Daiichi Sankyo (TYO: 4568), a leading pharmaceutical company in Japan, reported a significant year-on-year (YOY)...
NICE and AstraZeneca Fail to Reach Agreement on Enhertu Reimbursement for NHS
The UK’s National Institute for Health and Care Excellence (NICE) has announced that negotiations with...
Daiichi Sanky’s Mirogabalin Gets Green Light from China for Diabetic Neuropathic Pain
Daiichi Sanky (TYO: 4568), a pharmaceutical company based in Japan, has announced that it has...
Merck’s HER3-Targeted ADC Patritumab Deruxtecan Faces FDA Complete Response Letter
Merck, Sharp & Dohme Inc. (NYSE: MRK), a leading U.S. pharmaceutical company, has announced that...